Hashmonaim, Israel

David Aviezer


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:

goldMedal1 out of 832,966 
Other
 patents

Years Active: 2004

Loading Chart...
1 patent (USPTO):Explore Patents

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I will create an article about inventor David Aviezer based on the given data.

Title: The Innovative Work of David Aviezer in Pharmaceutical Compositions

Introduction:

David Aviezer, a talented inventor, hails from Hashmonaim, IL, and has made significant contributions to the field of pharmaceutical compositions.

Latest Patents:

David Aviezer holds one patent for his groundbreaking work on pharmaceutical compositions comprising porphyrins and novel porphyrin derivatives. The patent focuses on tertrapyrrolic macrocycles selected from 5,10,15,20-tetraaryl-porphyrins and 5,10,15-triaryl-corrloes, showcasing his expertise in inhibiting growth factor receptor tyrosine kinase activity.

Career Highlights:

Throughout his career, David Aviezer has demonstrated a passion for developing innovative pharmaceutical solutions. His patent on porphyrins and their derivatives highlights his dedication to advancing treatments for various disorders, including atherosclerosis, hypertrophic heart failure, and postsurgical restenosis.

Collaborations:

David Aviezer has collaborated with esteemed individuals in the field, including Avner Yayon and Zeev Gross. These collaborations have enriched his work and contributed to the success of his innovative pharmaceutical compositions.

Conclusion:

In conclusion, David Aviezer's pioneering work in pharmaceutical compositions has paved the way for novel treatments targeting growth factor receptor tyrosine kinase activity. His dedication to innovation and collaboration underscores his commitment to advancing the field of pharmaceuticals for the betterment of healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…